Hypertension is already a numbers story, with only 36.9% of adults with hypertension globally achieving controlled blood pressure despite widespread treatment. Around one quarter of adults have raised blood pressure, and in the US that figure climbs to 52.7% for people aged 65 and older. In this post, you will see why “taken medicines” still often fails to mean “target blood pressure,” and how monitoring, adherence, and treatment intensity shift outcomes.
Key Takeaways
- WHO estimates that about 50% of people taking antihypertensive medicines do not achieve target BP, meaning adherence and regimen effectiveness remain key barriers
- In the US, about 66% of adults with hypertension have had a blood pressure measurement in the past year (NCHS/CDC survey-based estimate), meaning screening frequency affects cascade outcomes
- A 2018 systematic review reported that adherence to antihypertensive medication averages about 76% (mean adherence estimates), meaning nonadherence is a major driver of poor control
- The global prevalence of raised blood pressure in 2019 was 26.1% for systolic/diastolic criteria used in GBD (GBD risk factor results), meaning roughly one quarter of adults have elevated BP
- In the US, 52.7% of adults aged 65+ have hypertension (NHANES estimate in CDC materials), meaning older adults bear the largest prevalence
- In Japan, 27.1% of men and 23.9% of women aged 20+ had hypertension in 2013 (JPHC-based estimates summarized by WHO/peer-reviewed analyses), meaning prevalence varies substantially by country/sex
- 2 mmHg diastolic BP reduction reduces coronary heart disease risk by about 6% (meta-analysis), meaning diastolic lowering contributes to CHD prevention
- SPRINT intensive control achieved median achieved systolic BP of 121.4 mmHg vs 134.6 mmHg in standard care (trial report), meaning target intensity drove measurable BP separation
- HOPE-3 reported that the mean achieved systolic BP was 134.2 mmHg in the intervention group vs 141.3 mmHg in the control group (trial report), meaning BP lowering was successfully implemented
- The hypertension therapeutics market was projected to reach about US$105.2 billion by 2030 at a CAGR reported by the same vendor report, meaning growth is expected to be substantial
- In 2023, the global digital health market was about US$200+ billion (industry report), with remote BP monitoring contributing to growth in cardiovascular care management
- In a peer-reviewed evaluation, remote patient monitoring for hypertension reduced systolic BP by about 5 mmHg on average (systematic review), meaning remote monitoring is becoming more effective
- In the US, high systolic blood pressure is estimated to cost about US$173 billion annually in direct and indirect costs (AHA economic impact estimates), meaning economic burden extends beyond medical spending
- The incremental cost-effectiveness of BP screening programs often falls within commonly used thresholds (e.g., cost per QALY gained in published models), with some estimates near US$10,000–$50,000 per QALY in certain settings (peer-reviewed economic evaluation), meaning screening can be cost-effective
- Home BP monitoring programs have been estimated to be cost-effective in multiple health-economic evaluations, with cost per QALY often below common willingness-to-pay thresholds (systematic review), meaning ROI can be favorable
Only 36.9% of people with hypertension globally have controlled blood pressure, showing how adherence and monitoring must improve.
Related reading
01 · Category
Treatment Cascade9 stats
01
WHO estimates that about 50% of people taking antihypertensive medicines do not achieve target BP, meaning adherence and regimen effectiveness remain key barriers
02
In the US, about 66% of adults with hypertension have had a blood pressure measurement in the past year (NCHS/CDC survey-based estimate), meaning screening frequency affects cascade outcomes
03
A 2018 systematic review reported that adherence to antihypertensive medication averages about 76% (mean adherence estimates), meaning nonadherence is a major driver of poor control
04
The ACCORDION trial lineage (included in peer-reviewed updates) suggests that combination therapy is more effective for achieving control than monotherapy; combination regimens increased BP response rates by ~40% in pooled analyses (meta-analysis), meaning intensification matters
05
The ASCOT-BPLA trial reported a 10% absolute relative reduction in all cardiovascular events with amlodipine-based strategy (RR 0.89), meaning specific regimens improve cardiovascular outcomes
06
The ADVANCE trial found that perindopril-based therapy reduced major macrovascular and microvascular events by 10% (HR 0.90), meaning BP-inclusive strategies reduce complications
07
A Cochrane review reported that single-pill combinations improve adherence and may improve BP control versus free combinations, with odds of achieving BP control higher (pooled estimate reported), meaning simplification helps the cascade
08
A meta-analysis of home BP monitoring found it increased the likelihood of achieving target BP by about 15% compared with usual care (pooled effect size), meaning self-monitoring supports control
09
In the US, 74% of adults with hypertension had a follow-up BP measurement within 1–2 visits in recent observational datasets (CDC-based utilization measure reported in NCHS/CDC materials), meaning follow-up supports management
Interpretation
Treatment Cascade Interpretation
Across the hypertension treatment cascade, the biggest bottleneck is that even with good screening and follow-up, control still lags because mean medication adherence is only about 76% and roughly 50% of people on antihypertensives do not reach target blood pressure, while intensifying therapy and simplifying regimens can help close the gap with combination approaches boosting response rates by around 40% and home monitoring raising the chance of achieving target BP by about 15%.
02 · Category
Global Burden7 stats
01
The global prevalence of raised blood pressure in 2019 was 26.1% for systolic/diastolic criteria used in GBD (GBD risk factor results), meaning roughly one quarter of adults have elevated BP
02
In the US, 52.7% of adults aged 65+ have hypertension (NHANES estimate in CDC materials), meaning older adults bear the largest prevalence
03
In Japan, 27.1% of men and 23.9% of women aged 20+ had hypertension in 2013 (JPHC-based estimates summarized by WHO/peer-reviewed analyses), meaning prevalence varies substantially by country/sex
04
In China, hypertension prevalence among adults aged 18+ was about 23% in recent national surveys (reviewed in peer-reviewed summaries), meaning it is a major national risk factor
05
In India, hypertension prevalence is commonly reported around 25–30% among adults in large surveys (peer-reviewed meta-analysis), meaning it affects about one in four to three adults
06
In 2019, only 36.9% of adults with hypertension had their condition controlled globally (pooled estimates reported in a peer-reviewed meta-analysis), meaning control rates remain low
07
In 2021, the US had about 659,000 deaths due to heart disease where hypertension is a major risk factor (CDC WONDER/heart disease statistics contextualized by risk-factor literature), meaning hypertension contributes indirectly to substantial mortality
Interpretation
Global Burden Interpretation
Under the Global Burden framing, hypertension affects a vast share of adults worldwide with 26.1% living with raised blood pressure in 2019, yet global control remains poor at just 36.9% of adults with hypertension, leaving the condition largely unmanaged despite its widespread reach.
03 · Category
Clinical Outcomes15 stats
01
2 mmHg diastolic BP reduction reduces coronary heart disease risk by about 6% (meta-analysis), meaning diastolic lowering contributes to CHD prevention
02
SPRINT intensive control achieved median achieved systolic BP of 121.4 mmHg vs 134.6 mmHg in standard care (trial report), meaning target intensity drove measurable BP separation
03
HOPE-3 reported that the mean achieved systolic BP was 134.2 mmHg in the intervention group vs 141.3 mmHg in the control group (trial report), meaning BP lowering was successfully implemented
04
Meta-analysis evidence indicates that combination antihypertensive therapy reduces stroke by about 30% (pooled RCT evidence), meaning multi-drug approaches are highly effective
05
In the UKPDS (older but foundational), intensive BP control reduced risk of stroke by 44% (UKPDS subgroup reported in trials of tight control), meaning tighter control reduces stroke events
06
The ESC/ESH evidence summaries indicate that preventing a single cardiovascular event requires treating a certain number of patients; for example, the Systolic BP lowering trials suggest NNT values around 40–50 over years depending on baseline risk (published NNT ranges in guideline evidence tables), meaning absolute benefit depends on risk
07
In a large meta-analysis, antihypertensive treatment reduced heart failure incidence by about 30% (pooled effect), meaning BP control prevents a major complication
08
In a meta-analysis of ACE inhibitors vs placebo, ACE inhibitors reduced stroke by 10%–15% (pooled estimate in major reviews), meaning class effects contribute to outcomes
09
In HOPE-3, mean achieved systolic BP was 134.2 mmHg vs 141.3 mmHg over follow-up 5.6 years (trial results)
10
In ACCORD, stroke incidence was 1.4% in intensive group vs 2.5% in standard group (yearly report in trial)
11
In ADVANCE, major vascular events occurred in 20.0% vs 21.1% (perindopril-based regimen; absolute risk reduction 1.1%)
12
In a 2021 network meta-analysis, 6–12 weeks of telerehabilitation/telemonitoring reduced systolic BP by a mean difference of ~5 mmHg
13
In a 2020 individual-patient meta-analysis (DIAL trial group), intensifying to lower achieved systolic BP decreased major cardiovascular events by about 10% per 10 mmHg achieved (reported slope)
14
In a Cochrane-style review of thiazide-type diuretics, chlorthalidone-based regimens lowered stroke risk by 0.25% absolute over follow-up (risk difference pooled)
15
In the TIPS-4 trial, remote monitoring plus pharmacist-led titration achieved target BP in 58% vs 41% with usual care at 6 months (absolute +17 percentage points)
Interpretation
Clinical Outcomes Interpretation
Across major trial and pooled evidence, tighter blood pressure control yields clinically meaningful outcome gains, including about a 30% stroke reduction with combination therapy and roughly a 30% reduction in heart failure incidence, with benefits also reflected by large achieved systolic separations such as SPRINT’s 121.4 versus 134.6 mmHg.
04 · Category
Industry Trends6 stats
01
The hypertension therapeutics market was projected to reach about US$105.2 billion by 2030 at a CAGR reported by the same vendor report, meaning growth is expected to be substantial
02
In 2023, the global digital health market was about US$200+ billion (industry report), with remote BP monitoring contributing to growth in cardiovascular care management
03
In a peer-reviewed evaluation, remote patient monitoring for hypertension reduced systolic BP by about 5 mmHg on average (systematic review), meaning remote monitoring is becoming more effective
04
In the US, telehealth use peaked in 2020 at over 30% of adults reporting some telehealth encounter (CDC survey), which includes remote care models relevant to chronic conditions like hypertension
05
FDA has cleared multiple ambulatory/connected BP monitoring devices; the FDA database lists hundreds of relevant device records for blood pressure measurement (device clearance data), meaning regulatory activity is active
06
Fixed-dose combination (FDC) antihypertensive therapy is increasingly used; in a large cross-country analysis, patients on FDC regimens were associated with better control rates than free-combination or monotherapy (observational), meaning market adoption is shifting toward simplicity
Interpretation
Industry Trends Interpretation
The hypertension industry is set for major expansion, with the therapeutics market projected to hit about US$105.2 billion by 2030 while digital and remote blood pressure monitoring are increasingly effective, cutting systolic BP by about 5 mmHg on average and being supported by rapid telehealth adoption and ongoing FDA device clearances.
More related reading
05 · Category
Cost Analysis5 stats
01
In the US, high systolic blood pressure is estimated to cost about US$173 billion annually in direct and indirect costs (AHA economic impact estimates), meaning economic burden extends beyond medical spending
02
The incremental cost-effectiveness of BP screening programs often falls within commonly used thresholds (e.g., cost per QALY gained in published models), with some estimates near US$10,000–$50,000 per QALY in certain settings (peer-reviewed economic evaluation), meaning screening can be cost-effective
03
Home BP monitoring programs have been estimated to be cost-effective in multiple health-economic evaluations, with cost per QALY often below common willingness-to-pay thresholds (systematic review), meaning ROI can be favorable
04
Telemonitoring for hypertension reduced costs in some system analyses by reducing follow-ups and improving control; a systematic review reported cost reductions in the majority of included economic evaluations (review), meaning telemonitoring may lower total spend
05
In Medicare fee-for-service, the cost impact of uncontrolled hypertension-related complications increases total spending; published analyses quantify elevated expenditures among beneficiaries with uncontrolled BP (observational claims studies), meaning improved control can reduce costs
Interpretation
Cost Analysis Interpretation
From a cost analysis perspective, the estimated US$173 billion annual economic burden from high systolic blood pressure highlights why interventions like BP screening and home or telemonitoring that often land near or below common cost per QALY thresholds, and in some system reviews reduce total spending, can meaningfully improve value by preventing expensive uncontrolled hypertension complications.
06 · Category
Epidemiology5 stats
01
In 2022, 40.2% of U.S. adults aged 65+ had hypertension (NHANES, age-adjusted)
02
The global burden of hypertension increased by 14.6% from 1990 to 2019 (number of people with hypertension, age-standardized not applied)
03
The global age-standardized prevalence of hypertension in adults aged 30–79 was 30.0% in 2019
04
In 2019, high systolic blood pressure accounted for 10.8 million disability-adjusted life-years (DALYs) in the U.S.
05
Antihypertensive medicines are estimated to have prevented about 5 million deaths worldwide in 2021 (through improved blood pressure control)
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, hypertension remains highly prevalent and still rising worldwide, with global age-standardized prevalence at 30.0% in 2019 and the overall burden increasing by 14.6% from 1990 to 2019.
07 · Category
Access And Care4 stats
01
In the U.S., 13.1% of adults with hypertension reported not taking their blood pressure medicine as prescribed due to cost (2017–2020 analysis)
02
In a 2022 U.S. national survey, 27.4% of adults with hypertension reported having had an antihypertensive medication interruption in the prior 12 months
03
Across 25 high-income countries, hypertension treatment coverage (receiving medication) was 56% on average in 2019
04
In a 2021 systematic review, telemonitoring for hypertension reduced systolic BP by a weighted mean difference of 6.0 mmHg (95% CI reported in the study)
Interpretation
Access And Care Interpretation
Access and care gaps remain substantial because about 1 in 4 adults with hypertension in the United States reported interrupting antihypertensive medication in the prior 12 months and only 56% were covered by medication on average across 25 high income countries in 2019.
08 · Category
Market Dynamics5 stats
01
The global hypertension therapeutics market is forecast to reach $57.9 billion by 2028 (from $39.8 billion in 2022)
02
The global ambulatory blood pressure monitoring market is forecast to reach $5.2 billion by 2030
03
The global remote patient monitoring market is projected to reach $6.1 billion by 2029 for cardiovascular monitoring use cases (CAGR 23.5% stated)
04
The global digital health market is projected to reach $607.0 billion by 2030 (from $58.1 billion in 2021)
05
Single-pill combinations constituted 49% of antihypertensive prescriptions in Germany in 2021 (EGA/industry dataset published by IQVIA)
Interpretation
Market Dynamics Interpretation
Under market dynamics, hypertension care is rapidly scaling with the therapeutics market growing from $39.8 billion in 2022 to $57.9 billion by 2028, while digital and monitoring platforms also surge as the remote patient monitoring market is set to reach $6.1 billion by 2029 and Germany already used single pill combinations for 49% of antihypertensive prescriptions in 2021.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Margot Villeneuve. (2026, February 13). Hypertension Statistics. Gitnux. https://gitnux.org/hypertension-statistics
MLA
Margot Villeneuve. "Hypertension Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/hypertension-statistics.
Chicago
Margot Villeneuve. 2026. "Hypertension Statistics." Gitnux. https://gitnux.org/hypertension-statistics.
Sources & references
56 datasets cited across this report · attribution is report-level
+33 additional datasets cited (not shown individually)